Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology

SAN DIEGO–(BUSINESS WIRE)–Janux closed a $56 million Series A financing led by Avalon Ventures and joined by OrbiMed, RA Capital Management, Bregua, and Correlation Ventures.